Cart
sales@molnova.com
Nimotuzumab
CAS No. 828933-51-3
Nimotuzumab( —— )
Catalog No. M28966 CAS No. 828933-51-3
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 1962 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNimotuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionNimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
-
DescriptionNimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number828933-51-3
-
Formula Weight——
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Chen JB, et al. Design and synthesis of novel dual-action compounds targeting the adenosine A(2A) receptor and adenosine transporter for neuroprotection. ChemMedChem. 2011 Aug 1;6(8):1390-1400.
molnova catalog
related products
-
Theliatinib
Theliatinib a potent and highly selective EGFR inhibitor with anti-tumor activity. Ki of 0.05 nM for wild type EGFR and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant respectively.
-
Pyrotinib
Pyrotinib (SHR-1258)?is a potent and selective EGFR/HER2 dual inhibitor with IC50 of 13/38 nM, respectively.
-
Tarlox-TKI
Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, with antitumor activity.Tarlox-TKI inhibits NRG1 and suppresses HER2 mutants.
